Abli Therapeutics INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersAtlanta, GA
SAM.gov UEIZ6F2VWKXRXL9
ABLi Therapeutics develops small molecule inhibitors targeting Abelson Tyrosine Kinases (Abl kinases) to treat neurodegenerative diseases, particularly Parkinson's disease and Parkinson's-related conditions. The company uses its proprietary RAMP (Re-engineering Approach with Metabolism Preserved) drug innovation engine to design product candidates with enhanced brain penetration.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Abli Therapeutics INC | Atlanta | GA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.